Aptevo Therapeutics Inc.
APVO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.61
KIRA · Stoqly’s AI analyst, in plain words
- Aptevo Therapeutics Inc. lost $26.0M in fiscal 2025.
Market cap
$1.9M
P/E
0.0x
Revenue
—
Net income
−$26.0M
Free cash flow
—
Operating margin
—
Aptevo Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$26.0M
No. It lost money last year.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
What Aptevo Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Aptevo Therapeutics Inc.
- CIK
- 0001671584
Aptevo Therapeutics Inc. · APVO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $12.3M | $3.1M | — | — | — |
| Revenue growth | 185.3% | −74.7% | — | — | — |
| Operating margin | −174.1% | −919.7% | — | — | — |
| Net income | −$28.5M | $8.0M | −$17.4M | −$24.1M | −$26.0M |
| Net margin | −231.5% | 257.8% | — | — | — |
| Diluted EPS | −$6.07 | $1.57 | −$2,316.83 | −$31,460.23 | −$87.27 |
| Cash | |||||
| Cash from operations | −$21.7M | −$21.0M | −$11.7M | −$23.8M | −$25.6M |
| Capital expenditure | $0.7M | $0.0M | — | — | — |
| Free cash flow | −$22.4M | −$21.1M | — | — | — |
| FCF margin | −182.2% | −676.0% | — | — | — |
| Share count change | 38.3% | 8.9% | −99.9% | −89.3% | 39,337.5% |
| Debt and strength | |||||
| Cash and short-term investments | $45.0M | $22.6M | $16.9M | $8.7M | $21.6M |
| Debt incl. finance leases | $16.0M | $4.0M | $0.0M | — | — |
| Shareholders' equity | $1.2M | $18.0M | $12.2M | $4.8M | $17.4M |
| Current ratio | 1.5x | 3.2x | 2.6x | 1.7x | 3.8x |
| Returns and quality | |||||
| Return on equity | −319.6% | 83.7% | −115.3% | −284.3% | −234.6% |
| Return on tangible equity | −2,340.2% | 44.7% | −142.5% | −507.5% | −158.4% |
| Piotroski F-score | 3 | 4 | 3 | — | — |
| Altman Z'' | −12.8 | −20.5 | −33.0 | −60.0 | −33.5 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aptevo Therapeutics Inc. · APVO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.61 a share, the company is worth $1.9M: 0.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001671584). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.